- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00070109
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the response rate in pediatric patients with recurrent or refractory soft tissue sarcomas or Ewing's sarcoma family of tumors treated with ecteinascidin 743 (trabectedin).
II. Determine the toxicity of this drug in these patients. III. Determine the pharmacokinetics of this drug in these patients.
OUTLINE:
Patients receive trabectedin IV over 3 hours on day 1. Treatment repeats every 21days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for up to 5 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 4L8
- Chedoke-McMaster Hospitals
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- Hospital Sainte-Justine
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Madera, California, United States, 93636-8762
- Children's Hospital Central California
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Childrens Memorial Hospital
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
New York, New York, United States, 10016
- New York University Langone Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- University of Vermont
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be greater than or equal to 12 months of age at the time of study entry and no more than 21 years of age when initially diagnosed with the malignancy to be treated on this protocol
Histologically confirmed recurrent or refractory sarcoma tumors, including the following:
- Rhabdomyosarcoma
- Nonrhabdomyosarcomatous soft tissue sarcoma
- Ewing's sarcoma
Measurable disease by imaging studies
- Lesions assessable only by radionuclide scans are not considered measurable
- If the only measurable lesion has been previously irradiated, then that lesion must have shown evidence of an interim increase in size
No significant amount of metastatic liver disease, defined as the following:
- Lesions occupying more than 25% of the liver by imaging and abnormal liver function tests or abnormal synthetic liver function
- Performance status - Lansky 50-100% (10 years of age and under)
- Performance status - Karnofsky 50-100% (over 10 years of age)
- Absolute neutrophil count at least 1,000/mm^3
- Platelet count at least 100,000/mm^3 (transfusion independent)
- Hemoglobin at least 8.0 g/dL (transfusion allowed)
No concurrent CYP3A4 inhibitors, including the following:
- Grapefruit juice
- Erythromycin
- Azithromycin
- Clarithromycin
- Rifampin and its analogs
- Fluconazole
- Ketoconazole
- Itraconazole
- Cimetidine
- Cannabinoids (marijuana or dronabinol)
- Leukotriene inhibitors used in asthma (e.g., zafirlukast, montelukast, or zileuton)
- Bilirubin no greater than upper limit of normal (ULN)
- Total alkaline phosphatase no greater than ULN
- Hepatic fraction alkaline phosphatase and 5 nucleotidase no greater than ULN
- SGOT and SGPT ≤ 2.5 times ULN
- Albumin ≥ 2.5 g/dL
- Gamma-glutamyl transferase < 2.5 times ULN
Maximum creatinine based on age as follows:
- 0.8 mg/dL (5 years of age and under)
- 1.0 mg/dL (6 to 10 years of age)
- 1.2 mg/dL (11 to 15 years of age)
- 1.5 mg/dL (over 15 years of age)
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) at least 70 mL/min
- No uncompensated congestive heart failure within the past 6 months
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for 2 months after study participation
- No active uncontrolled infection
- Weight ≥ 15 kilograms
- More than 1 week since prior growth factors that support platelet or white blood cell number or function
- At least 7 days since prior biologic agents and recovered
- No prior allogeneic stem cell transplantation
- No other concurrent immunomodulating agents
- More than 3 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
- No more than 2 prior multi-agent chemotherapy regimens
- No other concurrent anticancer chemotherapy
- Concurrent steroids allowed
- At least 6 weeks since prior since prior extended radiotherapy and recovered
- No prior total body radiotherapy
- Concurrent radiotherapy to localized painful lesions allowed provided at least 1 measurable lesion is not irradiated*
- At least 7 days since prior enzyme-inducing anticonvulsants (e.g., carbamazepine, phenobarbital, or phenytoin)
- No concurrent enzyme-inducing anticonvulsants
- No other concurrent investigational agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Trabectedin 1.3 mg/m2 to assess feasibility in all patients
Patients receive trabectedin over 3 hours on day 1.
Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
A cohort of 6 patients will be enrolled at the 1.3 mg/m2 dose level.
|
Correlative studies
Other Names:
Given IV
Other Names:
|
Experimental: Trabectedin 1.5 mg/m2 to assess feasibility in all patients
Patients receive trabectedin over 3 hours on day 1.
Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
Six toxicity-evaluable patients are assigned this treatment.
|
Correlative studies
Other Names:
Given IV
Other Names:
|
Experimental: Trabectedin at 1.5 mg/m2 to assess efficacy in Ewing sarcoma
Patients receive trabectedin over 3 hours on day 1.
Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Other Names:
Given IV
Other Names:
|
Experimental: Trabectedin at 1.5 mg/m2 - assess efficacy in rhabdomyosarcoma
Patients receive trabectedin over 3 hours on day 1.
Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Other Names:
Given IV
Other Names:
|
Experimental: Trabectedin 1.5 mg/m2 - assess efficacy in nonrhabdomyosarcoma
Patients receive trabectedin over 3 hours on day 1.
Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response (Complete Response [CR] and Partial Response [PR])
Time Frame: Twenty-six (26) cycles of chemotherapy or termination of protocol therapy, whichever occurs first.
|
Any patient who is enrolled and receives at least one dose of trabectedin will be considered evaluable for response if the individual receives at least one dose of trabectedin and: (1) is removed from protocol therapy because of progressive disease where progressive disease is documented either by imaging studies or clinical progression; or (2) has at least one radiographic evaluation of disease status after the start of protocol therapy and is not electively removed from protocol therapy with stable disease or is not lost to follow-up with stable disease.
Patients who achieve a complete response (CR) - disappearance of all target lesions or partial response (PR) - >=30% decrease in the sum of the longest diameter of target lesions according to the RECIST criteria will be considered responders for the study design.
All other patients who are evaluable for response will be considered non-responders for the study.
|
Twenty-six (26) cycles of chemotherapy or termination of protocol therapy, whichever occurs first.
|
Number of Patients With Dose-Limiting Toxicity (DLT)
Time Frame: 1 Cycle
|
Any Grade 3 or Grade 4 non-hematologic toxicity attributable to the Investigational drug with the specific exclusion of: Grade 3 nausea and vomiting; Grade 3 transaminase (AST/ALT) elevation that return to less than or equal to Grade 1 or baseline prior to the time for the next treatment cycle; Grade 3 fever or infection; Alopecia; Grade 4 neutropenia of > 7 days duration or Grade 4 thrombocytopenia of > 7 days duration, which requires transfusion therapy on greater than 2 occasions in 7 days, or which causes a delay of more than 14 days beyond the planned interval between treatment cycles.
|
1 Cycle
|
Pharmacokinetics by a Miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method : Maximum Plasma Concentration (Cmax) of Trabectedin
Time Frame: From baseline up to168 hours after trabectedin infusion in course 1
|
The plasma concentrations at each time point were determined by miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method.
The plasma concentration-versus-time data of trabectedin were estimated using non-compartmental methods.
Individual time points were not available, so one estimated Cmax was derived for each patient.
|
From baseline up to168 hours after trabectedin infusion in course 1
|
Pharmacokinetics by a Miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method : Apparent Volume at Steady State (Vss) of Trabectedin
Time Frame: From baseline up to168 hours after trabectedin infusion in course 1
|
The plasma concentrations at each time point were determined by miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method.
The plasma concentration-versus-time data of trabectedin were estimated using non-compartmental methods.
Individual time points were not available, so one estimated Vss was derived for each patient.
|
From baseline up to168 hours after trabectedin infusion in course 1
|
Pharmacokinetics by a Miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method : Half-life of Trabectedin
Time Frame: From baseline up to168 hours after trabectedin infusion in course 1
|
The plasma concentrations at each time point were determined by miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method.
The plasma concentration-versus-time data of trabectedin were estimated using non-compartmental methods.
Individual time points were not available, so one estimated Half-life was derived for each patient.
|
From baseline up to168 hours after trabectedin infusion in course 1
|
Pharmacokinetics by a Miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method : Area Under the Curve (AUC) of Trabectedin
Time Frame: From baseline up to168 hours after trabectedin infusion in course 1
|
The plasma concentrations at each time point were determined by miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method.
The plasma concentration-versus-time data of trabectedin were estimated using non-compartmental methods.
Individual time points were not available, so one estimated AUC was derived for each patient.
|
From baseline up to168 hours after trabectedin infusion in course 1
|
Pharmacokinetics by a Miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method : Clearance of Trabectedin
Time Frame: From baseline up to168 hours after trabectedin infusion in course 1
|
The plasma concentrations at each time point were determined by miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method.
The plasma concentration-versus-time data of trabectedin were estimated using non-compartmental methods.
Individual time points were not available, so one estimated Clearance was derived for each patient.
|
From baseline up to168 hours after trabectedin infusion in course 1
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sylvain Baruchel, MD, Children's Oncology Group
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Neoplasms, Neuroepithelial
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Osteosarcoma
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Myosarcoma
- Sarcoma
- Recurrence
- Sarcoma, Ewing
- Rhabdomyosarcoma
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Rhabdomyosarcoma, Embryonal
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Trabectedin
Other Study ID Numbers
- ADVL0221
- U10CA098543 (U.S. NIH Grant/Contract)
- NCI-2009-00357 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CDR0000329999 (Other Identifier: Clinical Trials.gov)
- COG-ADVL0221 (Other Identifier: Children's Oncology Group)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Ewing Sarcoma
-
Technical University of MunichUnknownRecurrent Ewing Sarcoma | Recurrent Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Ewing Sarcoma | Metastatic Ewing SarcomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Ewing Sarcoma | Recurrent Osteosarcoma | Stage III Osteosarcoma AJCC v7 | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma | Metastatic Ewing Sarcoma | Unresectable Ewing Sarcoma | Unresectable OsteosarcomaFrance
-
National Cancer Institute (NCI)Active, not recruitingRefractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Refractory Ewing Sarcoma | Recurrent Alveolar Rhabdomyosarcoma | Refractory Alveolar RhabdomyosarcomaUnited States, Canada
-
National Cancer Institute (NCI)CompletedEwing Sarcoma of Bone | Peripheral Primitive Neuroectodermal Tumor | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Extraosseous Ewing SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnEwing Sarcoma of Bone | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) and other conditionsUnited States
-
Dana-Farber Cancer Institute1 Million 4 Anna Foundation; Carson Sarcoma Foundation; Teaming up to Fight Childhood... and other collaboratorsCompleted
-
University of OxfordAstellas Pharma Inc; European Organisation for Research and Treatment of Cancer... and other collaboratorsCompletedRefractory Ewing Sarcoma | Relapsed Ewing SarcomaUnited Kingdom, Germany, Netherlands, Italy, France
-
Eisai Inc.CompletedEwing Sarcoma | Rhabdomyosarcoma | Refractory or Recurrent Solid Tumors | Non-Rhabdomyosarcoma Soft Tissue SarcomaSpain, United Kingdom, Italy, France, Germany, Greece, Poland, Switzerland
Clinical Trials on pharmacological study
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Universitätsmedizin MannheimHeidelberg UniversityUnknownLung Cancer | Brain and Central Nervous System TumorsGermany
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Peloton Therapeutics, Inc.CompletedRecurrent GlioblastomaUnited States
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Visual Pathway Glioma | Childhood Central Nervous System Germ Cell Tumor | Childhood Central Nervous System Choriocarcinoma | Childhood Central... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary SyndromeUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage...United States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMyeloid Proliferations Associated With Down SyndromeUnited States, Canada, Australia, Puerto Rico